This research examines whether listed Ayurveda pharmaceutical companies in India differ from conventional pharmaceutical firms in four critical financial dimensions: investment efficiency, financing patterns, working capital management, and bankruptcy risk.
The study analyses data from two large cap Ayurveda firms (Dabur, Emami), one small cap Ayurveda firm (Aimil), and four major pharmaceutical companies (Sun Pharma, Dr. Reddy’s, Cipla, Divi’s Labs) over five years (2018 2024), split into pre-COVID and post COVID periods. Statistical techniques include Pearson correlation, paired sample t tests, and Altman’s Z’’ Score discriminant model. Capital expenditure shows a strong positive correlation with return on investment (pre-COVID r=0.603, p<0.01; post COVID r=0.450, p<0.05), confirming that expansion spending creates value. Ayurveda firms operate with marginally higher leverage (mean difference 2.72, p=0.061) and demonstrate significantly shorter cash conversion cycles (p<0.01), reflecting superior working capital efficiency. Despite higher debt, Ayurveda companies exhibit lower financial distress risk (mean Z’’ Score 3.42 vs. 2.98 for pharma). This is the first empirical study to apply financial discriminant and comparative models specifically to the listed Ayurveda segment. The results indicate that Ayurveda firms are not merely smaller versions of pharma companies but possess distinct financial strengths – particularly in operational liquidity – that offset their higher leverage. Investors may benefit from Ayurveda’s efficient asset utilisation and low distress risk. Managers can leverage working capital efficiency as a competitive advantage. Policymakers should continue supporting the sector’s R&D infrastructure to sustain its healthy financial trajectory.